Diamyd Medical AB (FRA:DMN) YoY EBITDA Growth : -42.31% (As of Feb. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Diamyd Medical AB's YoY EBITDA Growth for the quarter that ended in Feb. 2025 was -42.31%.

Diamyd Medical AB's EBITDA per Share for the three months ended in Feb. 2025 was €-0.04.

Diamyd Medical AB YoY EBITDA Growth Historical Data

The historical data trend for Diamyd Medical AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB YoY EBITDA Growth Chart

Diamyd Medical AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

YoY EBITDA Growth

Get a 7-Day Free Trial

128.00

500.00

-241.67

-0.84

-7.50

Diamyd Medical AB Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
YoY EBITDA Growth	Get a 7-Day Free Trial															7.14	-54.55	-5.41	6.90	-42.31

Diamyd Medical AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Diamyd Medical AB's YoY EBITDA Growth for the fiscal year that ended in Aug. 2024 is calculated as:

	YoY EBITDA Growth (A: Aug. 2024 )
=	(EBITDA per Share (A: Aug. 2024 )	-	EBITDA per Share (A: Aug. 2023 ))	/	\| EBITDA per Share (A: Aug. 2023 ) \|
=	(-0.129	-	-0.12)	/	\| -0.12 \|
=	-7.50 %

Diamyd Medical AB's YoY EBITDA Growth for the quarter that ended in Feb. 2025 is calculated as:

	YoY EBITDA Growth (Q: Feb. 2025 )
=	(EBITDA per Share (Q: Feb. 2025 )	-	EBITDA per Share (Q: Feb. 2024 ))	/	\| EBITDA per Share (Q: Feb. 2024 )) \|
=	(-0.037	-	-0.026)	/	\| -0.026 \|
=	-42.31 %

Diamyd Medical AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

DYMDF:USA DMYD B:Sweden

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines